Biotechnology

Techseriesinsight > Blog > News > Biotechnology

January 21, 2026
Business Wire
Biotechnology, News

Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer

A global leader in cell-free DNA and precision medicine, today announced the publication in npj Precision Oncology of the validation study for its Latitude tissue-free molecular residual disease assay (tfMRD) in colorectal...

January 20, 2026
Business Wire
Biotechnology, News

Scribe Therapeutics Projected to Enter the Clinic in Mid-2026 with STX-1150, a PCSK9-targeting CRISPR Epigenetic Silencing Therapy for Durable LDL-C Reduction

Scribe Therapeutics, Inc. (Scribe), a biotechnology company pioneering highly engineered CRISPR technologies designed to reshape the treatment of disease by enabling earlier intervention, improved outcomes, and longer, healthier lives,...

January 20, 2026
Business Wire
Biotechnology, News

Worldwide Clinical Trials Enters Definitive Agreement to Acquire Catalyst Clinical Research

A specialized oncology CRO, known for its expertise in early phase oncology trials and a strong biometrics and Functional Service Provider (FSP) model. Following the close of the transaction,...

January 19, 2026
Business Wire
Biotechnology, News

Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform

A leading precision oncology company, today announced a multi-year collaboration with Merck, known as MSD outside the United States and Canada, to support the development and commercialization of Merck’s...

January 19, 2026
Business Wire
Biotechnology, News

ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) in combination with pertuzumab for the first-line treatment of adult patients with...

January 19, 2026
Business Wire
Biotechnology, News

Median Technologies Reports Landmark 2025 Performance With Major Regulatory and Commercial Milestones Ahead in 2026

Median Technologies, manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based...

January 16, 2026
Business Wire
Biotechnology, News

Prime Healthcare Expands Mission in Illinois with Franciscan Health Olympia Fields

Prime Healthcare today announced it has entered into an asset purchase agreement with Franciscan Alliance to acquire Franciscan Health Olympia Fields, further expanding Prime’s mission-driven presence in Chicagoland and...

January 16, 2026
Business Wire
Biotechnology, News

Autobahn Therapeutics Presents New Preclinical Data at ACNP Annual Meeting Supporting Novel Restorative Neuroplasticity Mechanism of Elunetirom

Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the presentation of new preclinical data for elunetirom, the company’s lead...

January 13, 2026
Business Wire
Biotechnology, News

Arches Medical Rhode Island Reports Progress in Primary Care Turnaround, Expands Access Amid Statewide Capacity Shortage

As Rhode Island’s primary care system continues to face sustained strain, the state’s largest independent primary care practice made significant progress in 2025 strengthening operations and expanding access to...

January 12, 2026
Business Wire
Biotechnology, News

NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue

A leading provider of oncology diagnostic solutions that enable precision medicine, today announced preliminary fourth quarter and full-year 2025 revenue and also announced a transition of the Company’s Chief...